222 related articles for article (PubMed ID: 30887169)
1. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.
Suton P; Skelin M; Rakusic Z; Dokuzovic S; Luksic I
Eur Arch Otorhinolaryngol; 2019 May; 276(5):1275-1281. PubMed ID: 30887169
[TBL] [Abstract][Full Text] [Related]
2. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
3. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
Hu Q; Li F; Yang K
PeerJ; 2024; 12():e17391. PubMed ID: 38784388
[TBL] [Abstract][Full Text] [Related]
4. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
5. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
6. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
8. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
[TBL] [Abstract][Full Text] [Related]
10. Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.
Riaz N; Sherman E; Koutcher L; Shapiro L; Katabi N; Zhang Z; Shi W; Fury M; Wong R; Wolden S; Rao S; Lee N
Am J Clin Oncol; 2016 Feb; 39(1):27-31. PubMed ID: 24401670
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis.
Swain M; Kannan S; Srinivasan S; Agarwal JP; Gupta T
Clin Oncol (R Coll Radiol); 2022 Dec; 34(12):786-795. PubMed ID: 35387752
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
Ou D; Levy A; Blanchard P; Nguyen F; Garberis I; Casiraghi O; Scoazec JY; Janot F; Temam S; Deutsch E; Tao Y
Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD
Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of a 15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy.
Deschuymer S; Sørensen BS; Dok R; Laenen A; Hauben E; Overgaard J; Nuyts S
Strahlenther Onkol; 2020 Jun; 196(6):552-560. PubMed ID: 32080773
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts.
Lassen P; Huang SH; Su J; Waldron J; Andersen M; Primdahl H; Johansen J; Kristensen CA; Andersen E; Eriksen JG; Hansen CR; Alsner J; Lilja-Fisher J; Bratman SV; Ringash J; Kim J; Hope A; Spreafico A; de Almeida J; Xu W; O'Sullivan B; Overgaard J
Int J Cancer; 2022 Apr; 150(8):1329-1340. PubMed ID: 34792199
[TBL] [Abstract][Full Text] [Related]
18. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS.
Carey RM; Brody RM; Shimunov D; Shinn JR; Mady LJ; Rajasekaran K; Cannady SB; Lin A; Lukens JN; Bauml JM; Cohen RB; Basu D; O'Malley BW; Weinstein GS; Newman JG
Laryngoscope; 2021 Dec; 131(12):E2865-E2873. PubMed ID: 34076275
[TBL] [Abstract][Full Text] [Related]
19. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
20. Comparison of high-dose Cisplatin-based chemoradiotherapy and Cetuximab-based bioradiotherapy for p16-positive oropharyngeal squamous cell carcinoma in the context of revised HPV-based staging.
Onita B; Lester D R T; Iman A A; Jergin C; Shawn I
Rep Pract Oncol Radiother; 2018; 23(5):451-457. PubMed ID: 30210266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
